Literature DB >> 6456687

Epimers of moxalactam: in vitro comparison of activity and stability.

R Wise, P J Wills, K A Bedford.   

Abstract

Moxalactam exists in two epimeric forms, R and S. The in vitro activity of these two epimers was compared with that of material available for clinical and laboratory use (R + S moxalactam). Generally, R moxalactam was twice as active as the S form. The stability of R + S moxalactam was studied at 37, 20, 4 and -20 degrees C in buffer and serum. Only in serum at 37 degrees C was there any appreciable loss of activity (half-life, 8 h). The stability of R and S epimers was studied separately, and the composition of the resulting equilibrium was investigated. At 37 degrees C in serum, one-half of the excess of either R or S over the equilibrium mixture was converted into the equilibrium mixture in 1.5 h. The proportions of R to S in an equilibrium mixture in buffer were 50:50, but in serum they were 45:55. It is doubtful whether these differences in stability and activity will have any significant clinical importance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6456687      PMCID: PMC181627          DOI: 10.1128/AAC.20.1.30

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Semisynthetic -lactam antibiotics. 2. Synthesis and properties of D- and L- -sulfobenzylpenicillins.

Authors:  S Morimoto; H Nomura; T Fugono; T Azuma; J Minami
Journal:  J Med Chem       Date:  1972-11       Impact factor: 7.446

2.  In-vitro interaction of Shigella flexneri with leukocytes and HeLa cells.

Authors:  O Calabi
Journal:  J Infect Dis       Date:  1970 Jul-Aug       Impact factor: 5.226

3.  The pharmacokinetics of LY127935, a broad spectrum oxa-beta-lactam.

Authors:  R Wise; S Baker; N Wright; R Livingston
Journal:  J Antimicrob Chemother       Date:  1980-05       Impact factor: 5.790

4.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

5.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

6.  LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

  6 in total
  11 in total

Review 1.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

2.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

3.  Epimerization kinetics of moxalactam in frozen solution.

Authors:  N Hashimoto; T Ichihashi; E Yamamoto; K Hirano; M Inoue; H Tanaka; H Yamada
Journal:  Pharm Res       Date:  1988-05       Impact factor: 4.200

4.  Epimerization kinetics of moxalactam in frozen urine and plasma samples.

Authors:  N Hashimoto; T Ichihashi; K Hirano; H Yamada
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

5.  Developmental pharmacokinetics of moxalactam.

Authors:  M D Reed; S C Aronoff; C M Myers; M P Husak; J S Bertino; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

6.  Covalent binding of moxalactam to cephalosporinase of Citrobacter freundii.

Authors:  K Murakami; T Yoshida
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

7.  Human pharmacokinetics and antimicrobial activities of the temocillin epimers.

Authors:  E A Guest; R Horton; G Mellows; B Slocombe; A J Swaisland; T C Tasker; A R White
Journal:  Drugs       Date:  1985       Impact factor: 9.546

8.  Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers.

Authors:  H C Standiford; G L Drusano; C I Bustamante; G Rivera; A Forrest; B Tatem; J Leslie; M Moody
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 10.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.